Is Omnipod 5 cost effective for the management of type 1 diabetes among adults in France?
Authors' conclusion
- Considering the reported benefits on glycemic control and health-related quality of life, Omnipod 5 is a cost-effective alternative to continuous subcutaneous insulin infusion + continuous glucose monitoring for adults with type 1 diabetes in France.
Study context
- Population
- Adults with T1D in France (modelled; population from OP5–003 RCT)
- Comparison
- Omnipod 5 AID vs CSII + CGM
- Outcome
- Life-years, QALYs, incremental cost-effectiveness and cost-utility ratios
- Follow-up
- 50-year horizon (base case)
Methodological detailsIQVIA Core Diabetes Model (v9.5), French healthcare system and societal perspective, 50-year horizon (base case), inputs from OP5-003 RCT, Utility values based on Omnipod 5 EuroQoL 3-Dimensions data and literature sources
- IQVIA Core Diabetes Model (v9.5)
- French healthcare system and societal perspective
- 50-year horizon (base case)
- Inputs from OP5-003 RCT
- Utility values based on Omnipod 5 EuroQoL 3-Dimensions data and literature sources
Main finding
As reported in the abstract
Base case · 50-year horizon
- Life-years gained with Omnipod 5 vs CSII + CGM
- 0.373
- QALYs gained with Omnipod 5 vs CSII + CGM
- 1.568
- Incremental cost-utility ratio (direct costs, healthcare perspective)
- €791 per quality-adjusted life-year
- Direct healthcare costs higher with Omnipod 5
- €1240
- Total costs incl. societal productivity lower with Omnipod 5
- €3071
Further findings
Sensitivity analyses
- Direct cost-utility ratio with HbA1c treatment effect halved
- €2438 per quality-adjusted life-year
- Lower total costs with Omnipod 5 across time horizons and discounting
Original publication
Is Omnipod 5 cost effective for the management of type 1 diabetes among adults in France? Diabetes Metab. Published 16 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →